← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #901 OF 1,000 MOST-CITED

Identification of Persons Performing Significant Steps

FDA cited this observation 16 times across 16 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs16
BY FISCAL YEAR
FY20252
FY20241
FY20232
FY20222
FY20202
FY20195
FY20182

How FDA worded it — real examples

The batch production and control records are deficient in that they do not include identification of persons supervising each significant step in the operation.

Procter & Gamble Manufacturing Mexico, S. de R.L. de C.V. · Naucalpan · Drugs · 2025-06-27

The batch production and control records are deficient in that they do not include identification of persons performing, supervising and checking each significant step in the operation.

Jubilant Cadista Pharmaceuticals · Yardley, Pennsylvania · Drugs · 2025-01-15

The batch production and control records are deficient in that they do not include identification of persons each significant step in the operation.

B & J Group · Morrisville, Pennsylvania · Drugs · 2023-10-02

The batch production and control records are deficient in that they do not include identification of persons each significant step in the operation.

Elysium Pharmaceuticals Limited · Vadodara · Drugs · 2023-01-16

The batch production and control records are deficient in that they do not include identification of persons performing and checking each significant step in the operation.

Health Pharma USA LLC · Rahway, New Jersey · Drugs · 2022-12-20

The batch production and control records are deficient in that they do not include identification of persons each significant step in the operation.

Bentley Laboratories LLC · Edison, New Jersey · Drugs · 2022-08-17

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →